Search results
Results From The WOW.Com Content Network
The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion.
For premium support please call: 800-290-4726 more ways to reach us
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH ...
Mendlein is also a board member of Editas Medicine ( Nasdaq : EDIT ), Moderna Therapeutics and Axcella Health. He is a founder and director of Homes for Sudan, a non-profit organization providing sustainable, fireproof homes for displaced families in Sudan. He also serves on the Biotechnology Innovation Organization (“BIO”) emerging ...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps ...
Here are a few recommendations for biotech ETFs in 2024. 1. VanEck Biotech ETF (BBH) Top five holdings: Amgen, Vertex Pharmaceuticals, Gilead Sciences, Regeneron Pharmaceuticals, Moderna. Average ...
Cambridge, Massachusetts, U.S. Number of employees. 355 (March 31, 2024) Website. cerevel .com. Cerevel Therapeutics Holdings, Inc. is a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses. [1] Cerevel was established in October 2018, and is headquartered in Cambridge ...
William Rastetter. William H. (aka Bill) Rastetter (born 1948), a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, [4] and of Daré Bioscience, Inc. [5] in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a ...